investor-relations

RMD

NYSE: 130.45 +1.23 +0.95% Volume: 420,361 October 15, 2019
ASX: Volume:
$2.6 Billion
fiscal year 2019


9%
Adjusted EPS growth over the last five fiscal years

63%
free cash flow returned to shareholders over the last rolling five years

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

Latest Reports

Date Download
August 12, 2019 2019 Annual Report 1.61 MB
July 28, 2016 Current Investor Presentation 3.27 MB
June 16, 2015 ESG Report 1.04 MB

Email Alerts

Email Adress Email Address: *
Mailing Lists *





 
Enter the code shown above.